Clinical Trial Update: Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated pharmacogenetic treatment with anti-glutamatergic agents for individuals with comorbid PTSD and alcohol use disorder; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Post-traumatic Stress Disorder

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: PTSD, Alcohol Use Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-03-13